Effect of Covid-19 on Hypertension

Completed

• Conditions: COVID-19; Hypertension
• Interventions: Diagnostic Test: blood pressure measurement

• Registration Number: NCT05798208
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

In this single center , retrospective study, 5355 covid patient were selected from 2020 to 2022, with recorded blood pressure before covid and recording after covid. Blood pressure before and after covid were compared, by pair T test.

Detailed Description

design and participants This single-center retrospective cohort study was conducted at an outpatient cardiology clinic in Shiraz, Iran, between February 15, 2020, and December 28, 2022. We evaluated patients with a confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA reverse-transcriptase polymerase-chain-reaction assays from nasopharyngeal or oropharyngeal swab specimens according to World Health Organization guidelines (12). Two physicians (PA, MY) reviewed the patients' electronic medical records, including demographics, comorbidities, vital signs, treatments, and outcomes. Ambiguities were resolved by a third author (MM).

The current study included all COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery. The following patients were excluded: those under 18, with hospital admission due to COVID-19, who received corticosteroid therapy, those with a history of systemic inflammatory disease, kidney or liver, immunocompromised patients, and those who switched their antihypertensive regimen during the study. Finally, 5,355 eligible patients were investigated . The primary outcome was to assess BP variation following infection (particularly a prolonged rise in BP) among non-hospitalized COVID-19 patients. The secondary outcome was to identify the predictor factors of BP variation.

The present study was approved by the Ethics Committee of Shiraz University of Medical Sciences under code IR.SUMS.MED.REC.1401.465 , and the need for informed consent was waived due to the study's retrospective nature and the absence of patient identifiers in the presented data.

Study Timeline

• Study Start: 2020-02-15
• Primary Completion: 2022-12-28
• Study Completion: 2023-02-20
• Status Verified: 2023-04
• Study First Submitted: 2023-04-02
• Study First Submitted QC: 2023-04-02
• Last Update Submitted: 2023-04-02
• Study First Posted: 2023-04-04
• Last Update Posted: 2023-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5355

Inclusion Criteria

• All COVID-19 patients who had at least one documented blood pressure measurement in the three months preceding infection and one documented measurement one to three months following recovery

Exclusion Criteria

• Age under 18
• Hospital admission due to COVID-19
• Corticosteroid therapy,
• History of systemic inflammatory disease
• kidney disease
• liver disease
• Immunocompromised patients

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
hypertensive	blood pressure measurement	Covid patients with exacerbated hypertension or new hypertension post covid
non hypertensive	blood pressure measurement	Covid patients with no change in blood pressure pre and post covid

Primary Outcome Measures

Name	Time	Method
change of blood pressure	2 years	any change in blood pressure level before and after covid infection

Secondary Outcome Measures

Name	Time	Method
predictors of changes in blood pressure	2 years	history of any risk factor for cardiac disease, age, sex,

Trial Locations

Locations (3)

Education Developmen Center; 🇮🇷 Shiraz, Fars, Iran, Islamic Republic of

Professor kojuri cardiology clinic; 🇮🇷 Shiraz, Outside Of The US, Iran, Islamic Republic of

Cardiology Ward Shiraz University of Medical Sciences; 🇮🇷 Shiraz, Fars, Iran, Islamic Republic of